newsfilter
← Interviews
Goldman Sachs22 min

Why We’re In a ‘Golden Age’ of Life Sciences Innovation

Amit Sinha, Allison Nathan

Interview, Fireside Chat

With the life sciences sector valued at over $2 trillion and projected to surpass $5 trillion through innovations like mRNA and cell therapy, analysts Allison Nathan and Amit Sinha characterize the current climate as a golden era driven by advanced genetic tools and supportive regulation. Despite a decade-long market correction caused by unsustainable capital surges and increased clinical trial failures, the industry is adapting by shifting toward private capital scaling and downstream investments in companies with experienced management. This structural evolution aims to sustain the development of critical breakthroughs, such as gene therapies for spinal muscular atrophy and immunotherapies for rectal cancer, while navigating complex supply chain and biological challenges.